#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Comparison of whole body bone scintigraphy with levels of the serum concentration of human epididymal protein 4 in patients with malignant melanoma


Authors: Jaroslav Weissensteiner 1;  Eva Babušíková 2
Authors place of work: Oddelenie nukleárnej medicíny, Nemocnica Poprad, a. s., SR 1;  Ústav lekárskej biochémie, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, SR 2
Published in the journal: NuklMed 2015;4:8-12
Category: Original Article

Summary

Introduction:
Melanoma is the most dangerous type of skin cancer and it is the leading cause of death from skin disease. The annual incidence has increased dramatically over the past few decades. The aim of this study was to correlate serum levels of the tumour marker human epididymal protein 4 (HE4) with the presence of bone metastases detected by whole-body bone scintigraphy in patients with malignant melanoma and to evaluate the importance of HE4 in the malignant melanoma diagnostics.

Material and methods:
We determined HE4 in serum from blood sample in 14 patients (4 men, 10 women) with malignant melanoma. The blood sample was took before radioactive tracer application in whole-body bone scintigraphy examination by using hybrid gamma camera SPECT/CT (single photon emission computed tomography/computed tomography). We compared the results with 10 individuals without malignant disease – control group.

Results:
Bone metastases using whole-body bone scintigraphy were detected in 5 cases (35.71 %), probably in 3 cases (21.43 %) and 6 patients (42.86 %) were without bone metastases. The concentration of HE4 was significantly higher in patients than in individuals of control group. Serum concentration of HE4 was higher above reference range only in one patient with melanoma. The concentrations of HE4 in patients were not different and dependent on grade of bone metastases.

Conclusion:
We observed that serum concentration of HE4 in patients with malignant melanoma was higher comparing to individuals of control group. The serum concentrations of HE4 were not correlated with finding on whole-body bone scintigraphy.

Key words:
melanoma, human epididymal protein 4, bone scintigraphy


Zdroje

1. Bayraktutan U, Kantarci M, Pirimoglu B et al. Utility of diffusion-weighted imaging in the diagnosis of inguinal lymph node metastasis with malignant melanoma. World J Clin Cases 2014;2:42-44

2. Maire C, Vercambre-Darras S, Desmedt E. Diagnosis of melanoma. Rev Prat 2014;64:61-68

3. Bandarchii B, Jabbari CA, Vedadi A et al. Molecular biology of normal melanocytes and melanoma cells. J Clin Pathol 2013;66:644-648

4. Diba CS, Pleško I, Hlava P. Incidencia zhubných nádorov v Slovenskej republike 2007. Bratislava, NCZI, 2012, 135 s

5. Aladovicz E, Ferro L, Vitali GC et al. Molecular networks in melanoma invasion and metastasis. Future Oncol 2013;9:713-726

6. Zbytek B, Carlson JA, Granese J et al. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008;3:569-585

7. Bobrovská M, Minariková E, Plank L. Diagnostika malígneho melanómu. Onkológia 2009;4:144-148

8. Jain D, Singh T, Kumar N et al. Metastatic malignant melanoma in bone marrow with occult primary site – a case report with review of literature. Diagnostic Pathology 2007;2:38-41

9. Serrier C, Lesesve JF. Metastatic malignant melanoma in the bone marrow. Blood 2013;121:721

10. Potepan P, Spagnoli I, Danesini GM et al. The radiodiagnosis of bone metastases from melanoma. Radiol Med 1994;87:741-746

11. Votrubová J. Melanom. In: Votrubová J et al. Klinické PET a PET/CT. Praha, Galén, 2009; 159-162

12. Bastiaannet E, Wobbes T, Hoekstra OS et al. Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27:4774-4780

13. Barsky M, Cherkassky L, Vezederis M et al. The role of preoperative positron emission tomography/computed tomography (PET/CT) in patients with high-risk melanoma. J Surg Oncol 2014;109:726-729

14. Buchbender C, Heusner TA, Lauenstein TC et al. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012;53:1244-1252

15. Kirchhoff C, Habben I, Ivell R et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991;45:350-357

16. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod 1998;3:86-95

17. Bingle L, Cross SS, High AS et al. WFDC2 (HE4): a potential role in the innate imunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006;7:61-70

18. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002;368:233-242

19. Hellström I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-3700

20. Li J, Dowdy S, Tipton T et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-566

21. Moore RG, Hill EK, Horan T et al. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep 2014;4:3574-3580

22. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol 2006;19:847-853

23. Speeckaert MM, Speeckaert R, Delanghe JR. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem 2013;59:1-21

24. Escudero JM, Auge JM, Filella X et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-1544

25. Li J, Chen H, Mariani A et al. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci 2013;14:6026-6043

26. Karlsen NS, Karlsen MA, Hogdall CK et al. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumours – a systematic review. Cancer Epidemiol Biomarkers Prev 2014;23:2285-2295

Štítky
Nuclear medicine Radiodiagnostics Radiotherapy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#